{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:36:46Z","timestamp":1790397406833,"version":"4.1.0"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100014584","name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014584","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40263-025-01259-4","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T12:51:44Z","timestamp":1769691104000},"page":"333-357","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["New Pharmacological Treatment Approaches for Schizophrenia: Navigating the Post-iclepertin Landscape"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5604-2504","authenticated-orcid":false,"given":"Susanne","family":"Englisch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Zink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"1259_CR1","unstructured":"World Health Organization (WHO): Schizophrenia. 2022. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/schizophrenia. Accessed 23 Nov 2025."},{"issue":"2","key":"1259_CR2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","volume":"77","author":"RA McCutcheon","year":"2020","unstructured":"McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia\u2014an overview. JAMA Psychiatr. 2020;77(2):201\u201310.","journal-title":"JAMA Psychiatr"},{"key":"1259_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2022_382","volume-title":"Cognitive functioning in schizophrenia: leveraging the RDoC framework. Current topics in behavioral neurosciences","author":"WP Horan","year":"2022","unstructured":"Horan WP, Catalano LT, Green MF. An update on treatment of cognitive impairment associated with schizophrenia. In: Barch DM, Young JW, editors. Cognitive functioning in schizophrenia: leveraging the RDoC framework. Current topics in behavioral neurosciences, vol. 63. Cham: Springer; 2022. https:\/\/doi.org\/10.1007\/7854_2022_382."},{"issue":"19","key":"1259_CR4","doi-asserted-by":"publisher","first-page":"10668","DOI":"10.3390\/ijms251910668","volume":"25","author":"T Zhang","year":"2024","unstructured":"Zhang T, Liu C, Zhong N, Wang Y, Huang Y, Zhang X. Advances in the treatment of cognitive impairment in schizophrenia: targeting NMDA receptor pathways. Int J Mol Sci. 2024;25(19):10668\u201386.","journal-title":"Int J Mol Sci"},{"issue":"10039","key":"1259_CR5","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","volume":"388","author":"MJ Owen","year":"2016","unstructured":"Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016;388(10039):86\u201397.","journal-title":"Lancet"},{"key":"1259_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1146\/annurev-pharmtox-051921-093250","volume":"63","author":"DC Javitt","year":"2023","unstructured":"Javitt DC. Cognitive impairment associated with schizophrenia: from pathophysiology to treatment. Annu Rev Pharmacol Toxicol. 2023;63:119\u201341.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"Suppl 9","key":"1259_CR7","first-page":"3","volume":"67","author":"MF Green","year":"2006","unstructured":"Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry. 2006;67(Suppl 9):3\u20138 (discussion 36-42).","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"1259_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/jamapsychiatry.2024.2890","volume":"82","author":"L Feber","year":"2025","unstructured":"Feber L, Peter NL, Chiocchia V, Schneider-Thoma J, Siafis S, Bighelli I, et al. Antipsychotic drugs and cognitive function: a systematic review and network meta-analysis. JAMA Psychiatr. 2025;82(1):47\u201356.","journal-title":"JAMA Psychiatr"},{"issue":"2","key":"1259_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/wps.20648","volume":"18","author":"RSE Keefe","year":"2019","unstructured":"Keefe RSE. Why are there no approved treatments for cognitive impairment in schizophrenia? World Psychiatry. 2019;18(2):167\u20138.","journal-title":"World Psychiatry"},{"issue":"8","key":"1259_CR10","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40263-022-00935-z","volume":"36","author":"T Veselinovi\u0107","year":"2022","unstructured":"Veselinovi\u0107 T, Neuner I. Progress and pitfalls in developing agents to treat neurocognitive deficits associated with schizophrenia. CNS Drugs. 2022;36(8):819\u201358.","journal-title":"CNS Drugs"},{"issue":"2-3","key":"1259_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.pscychresns.2012.04.014","volume":"204","author":"JA Wojtalik","year":"2012","unstructured":"Wojtalik JA, Eack SM, Pollock BG, Keshavan MS. Prefrontal gray matter morphology mediates the association between serum anticholinergicity and cognitive functioning in early course schizophrenia. Psychiatry Res. 2012;204(2\u20133):61\u20137.","journal-title":"Psychiatry Res"},{"issue":"3","key":"1259_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0893-133X(98)00060-8","volume":"20","author":"JD Jentsch","year":"1999","unstructured":"Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1999;20(3):201\u201325.","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"1259_CR13","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1007\/s00213-023-06454-z","volume":"240","author":"A Janus","year":"2023","unstructured":"Janus A, Lustyk K, Pytka K. MK-801 and cognitive functions: investigating the behavioral effects of a non-competitive NMDA receptor antagonist. Psychopharmacology. 2023;240(12):2435\u201357.","journal-title":"Psychopharmacology"},{"key":"1259_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.107426","volume":"205","author":"K Nakazawa","year":"2020","unstructured":"Nakazawa K, Sapkota K. The origin of NMDA receptor hypofunction in schizophrenia. Pharmacol Ther. 2020;205:107426-107458.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"1259_CR15","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.neuropharm.2005.03.019","volume":"49","author":"AA Grishin","year":"2005","unstructured":"Grishin AA, Benquet P, Gerber U. Muscarinic receptor stimulation reduces NMDA responses in CA3 hippocampal pyramidal cells via Ca2+-dependent activation of tyrosine phosphatase. Neuropharmacology. 2005;49(3):328\u201337.","journal-title":"Neuropharmacology"},{"issue":"1","key":"1259_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyae066","volume":"28","author":"RT Terry-Lorenzo","year":"2024","unstructured":"Terry-Lorenzo RT, Fan RH, Khin NA, Singh JB. Therapeutic potential of D-amino acid oxidase inhibitors for cognitive impairment associated with schizophrenia: learnings from luvadaxistat. Int J Neuropsychopharmacol. 2024;28(1):pyae066. https:\/\/doi.org\/10.1093\/ijnp\/pyae066.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1259_CR17","unstructured":"Neurocrine Biosciences Inc. Neurocrine Biosciences Provides Update on ERUDITE\u2122 Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia. In: BioSpace. September 12, 2024. https:\/\/neurocrine.gcs-web.com\/news-releases\/news-release-details\/neurocrine-biosciences-provides-update-eruditetm-phase-2-data. Accessed 23 Nov 2025."},{"issue":"7","key":"1259_CR18","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s00406-023-01576-z","volume":"273","author":"H Rosenbrock","year":"2023","unstructured":"Rosenbrock H, Desch M, Wunderlich G. Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2023;273(7):1557\u201366.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"2","key":"1259_CR19","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s13318-017-0440-z","volume":"43","author":"V Moschetti","year":"2018","unstructured":"Moschetti V, Desch M, Goetz S, Liesenfeld KH, Rosenbrock H, Kammerer KP, et al. Safety, tolerability and pharmacokinetics of oral BI 425809, a glycine transporter 1 inhibitor, in healthy male volunteers: a partially randomised, single-blind, placebo-controlled, first-in-human study. Eur J Drug Metab Pharmacokinet. 2018;43(2):239\u201349.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"3","key":"1259_CR20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S2215-0366(20)30513-7","volume":"8","author":"WW Fleischhacker","year":"2021","unstructured":"Fleischhacker WW, Podhorna J, Gr\u00f6schl M, Hake S, Zhao Y, Huang S, et al. Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. Lancet Psychiatry. 2021;8(3):191\u2013201.","journal-title":"Lancet Psychiatry"},{"key":"1259_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.scog.2024.100340","volume":"40","author":"PD Harvey","year":"2025","unstructured":"Harvey PD, McDonald S, Fu E, Reuteman-Fowler C. Efficacy and safety of iclepertin (BI 425809) with adjunctive computerized cognitive training in patients with schizophrenia. Schizophr Res Cogn. 2025;40:100340. https:\/\/doi.org\/10.1016\/j.scog.2024.100340.","journal-title":"Schizophr Res Cogn"},{"issue":"12","key":"1259_CR22","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/S2215-0366(25)00296-2","volume":"12","author":"RSE Keefe","year":"2025","unstructured":"Keefe RSE, Harvey PD, Correll CU, Falkai P, Hashimoto N, Klein H, et al. Efficacy and safety of iclepertin for cognitive impairment associated with schizophrenia (CONNEX programme): results from three phase 3 randomised controlled trials. Lancet Psychiatry. 2025;12(12):906\u201320.","journal-title":"Lancet Psychiatry"},{"key":"1259_CR23","unstructured":"Boehringer-Ingelheim. Boehringer provides update on iclepertin Phase III program in schizophrenia. In: Press Releases. January 16, 2025. https:\/\/www.boehringer-ingelheim.com\/human-health\/mental-health\/schizophrenia\/update-phase-iii-connex-clinical- program-schizophrenia. Accessed 23 Nov 2025."},{"issue":"6","key":"1259_CR24","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jamapsychiatry.2014.163","volume":"71","author":"D Umbricht","year":"2014","unstructured":"Umbricht D, Alberati D, Martin-Facklam M, Borroni E, Youssef EA, Ostland M, et al. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiat. 2014;71(6):637\u201346.","journal-title":"JAMA Psychiat"},{"key":"1259_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2024.1389718","volume":"18","author":"P Singer","year":"2024","unstructured":"Singer P, Yee BK. Inhibition of astrocytic glycine transporter-1: friend or foe for ameliorating NMDA receptor hypofunction? Front Cell Neurosci. 2024;18:1389718. https:\/\/doi.org\/10.3389\/fncel.2024.1389718. (eCollection 2024).","journal-title":"Front Cell Neurosci"},{"issue":"4","key":"1259_CR26","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/JCP.0000000000000722","volume":"37","author":"JT Kantrowitz","year":"2017","unstructured":"Kantrowitz JT, Nolan KA, Epstein ML, Lehrfeld N, Shope C, Petkova E, et al. Neurophysiological effects of bitopertin in schizophrenia. J Clin Psychopharmacol. 2017;37(4):447\u201351.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"1259_CR27","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41398-022-02096-5","volume":"12","author":"C Schultheis","year":"2022","unstructured":"Schultheis C, Rosenbrock H, Mack SR, Vinisko R, Schuelert N, Plano A, et al. Quantitative electroencephalography parameters as neurophysiological biomarkers of schizophrenia-related deficits: a Phase II substudy of patients treated with iclepertin (BI 425809). Transl Psychiatry. 2022;12(1):329\u201337.","journal-title":"Transl Psychiatry"},{"key":"1259_CR28","doi-asserted-by":"crossref","unstructured":"Kim H, Choi S, Lee E, Koh W, Lee CJ. Tonic NMDA receptor currents in the brain: regulation and cognitive functions. Biol Psychiatry. 2024;96(3):164\u201375. 28.","DOI":"10.1016\/j.biopsych.2024.03.009"},{"key":"1259_CR29","unstructured":"Neurocrine Biosciences Inc. Neurocrine biosciences provides update on ERUDITE\u2122 phase 2 data for luvadaxistat in adults with cognitive impairment associated with schizophrenia. In: Bio Space. September 12, 2024. https:\/\/www.biospace.com\/drug-development\/neurocrine-biosciences-provides-update-on-erudite-phase-2-data-for-luvadaxistat-in-adults-with-cognitive-impairment-associated-with-schizophrenia. Accessed 23 Nov 2025."},{"issue":"2-3","key":"1259_CR30","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.schres.2013.08.020","volume":"150","author":"VL Stauffer","year":"2013","unstructured":"Stauffer VL, Millen BA, Andersen S, Kinon BJ, Lagrandeur L, Lindenmayer JP, et al. Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophr Res. 2013;150(2\u20133):434\u201341.","journal-title":"Schizophr Res"},{"key":"1259_CR31","unstructured":"Denovo Biopharma. Denovo Biopharma licenses late-stage neuroscience drug from lilly for development as a personalized medicine. In: Fierce Biotech. March 8, 2015. Press Release. March 8, 2015. https:\/\/www.fiercebiotech.com\/biotech\/denovo-biopharma-licenses-late-stage-neuroscience-drug-from-lilly-for-development-as-a. Accessed 23 Nov 2025."},{"issue":"11","key":"1259_CR32","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s40263-022-00959-5","volume":"36","author":"CY Kuo","year":"2022","unstructured":"Kuo CY, Lin CH, Lane HY. Targeting d-amino acid oxidase (DAAO) for the treatment of schizophrenia: rationale and current status of research. CNS Drugs. 2022;36(11):1143\u201353.","journal-title":"CNS Drugs"},{"issue":"11","key":"1259_CR33","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/d41573-024-00155-8","volume":"23","author":"K Kingwell","year":"2024","unstructured":"Kingwell K. FDA approves first schizophrenia drug with new mechanism of action since 1950s. Nat Rev Drug Discov. 2024;23(11):803.","journal-title":"Nat Rev Drug Discov"},{"key":"1259_CR34","unstructured":"U.S. Food and Drug Administration: FDA approves drug with new mechanism of action for treatment of schizophrenia. In: FDA News Release. September 16, 2024. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-drug-new-mechanism-action-treatment-schizophrenia?os=wtmb&ref=app. Accessed 23 Nov 2025."},{"key":"1259_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1421554","volume":"15","author":"SE Yohn","year":"2024","unstructured":"Yohn SE, Harvey PD, Brannan SK, Horan WP. The potential of muscarinic M(1) and M(4) receptor activators for the treatment of cognitive impairment associated with schizophrenia. Front Psychiatry. 2024;15:1421554. https:\/\/doi.org\/10.3389\/fpsyt.2024.1421554. (eCollection 2024).","journal-title":"Front Psychiatry"},{"issue":"12","key":"1259_CR36","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1080\/13543784.2023.2288074","volume":"32","author":"B Dean","year":"2023","unstructured":"Dean B. Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal. Expert Opin Investig Drugs. 2023;32(12):1113\u201321.","journal-title":"Expert Opin Investig Drugs"},{"key":"1259_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107510","volume":"210","author":"B Dean","year":"2024","unstructured":"Dean B. IUPHAR review on muscarinic M1 and M4 receptors as drug treatment targets relevant to the molecular pathology of schizophrenia. Pharmacol Res. 2024;210:107510. https:\/\/doi.org\/10.1016\/j.phrs.2024.107510.","journal-title":"Pharmacol Res"},{"issue":"10422","key":"1259_CR38","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","volume":"403","author":"I Kaul","year":"2024","unstructured":"Kaul I, Sawchak S, Correll CU, Kakar R, Breier A, Zhu H, et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet. 2024;403(10422):160\u201370.","journal-title":"Lancet"},{"issue":"8","key":"1259_CR39","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.biopsych.2024.03.014","volume":"96","author":"SM Paul","year":"2024","unstructured":"Paul SM, Yohn SE, Brannan SK, Neugebauer NM, Breier A. Muscarinic receptor activators as novel treatments for schizophrenia. Biol Psychiatry. 2024;96(8):627\u201337.","journal-title":"Biol Psychiatry"},{"key":"1259_CR40","unstructured":"Horan W, Sauder C, Harvey PD, Ramsay IS, Paul SM, Davis VG, Brannan SK. Further evaluation of the procognitive effect of KarXT in acutely symptomatic schizophrenia: consideration of cognitive subdomains and methodological factors. In: Conference proceedings from: The International Society for CNS Clinical Trials and Methodology (ISCTM) annual scientific meeting, Washington, DC. February 21\u201323, 2024. https:\/\/isctm.org\/public_access\/20th_Annual\/Abstract\/Horan_Abstract.pdf."},{"key":"1259_CR41","doi-asserted-by":"publisher","DOI":"10.1055\/a-2506-7022","author":"T Kishi","year":"2025","unstructured":"Kishi T, Citrome L, Sakuma K, Hamanaka S, Nishii Y, Hatano M, et al. Xanomeline-trospium for adults with schizophrenia experiencing acute psychosis: a systematic review and meta-analysis of safety and tolerability outcomes. Pharmacopsychiatry. 2025. https:\/\/doi.org\/10.1055\/a-2506-7022.","journal-title":"Pharmacopsychiatry"},{"key":"1259_CR42","unstructured":"Bristol Myers Squibb. Bristol Myers Squibb announces topline results from phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics in adults with schizophrenia. In: Corporate\/Financial News. April 22, 2025. https:\/\/news.bms.com\/news\/corporate-financial\/2025\/Bristol-Myers-Squibb-Announces-Topline-Results-from-Phase-3-ARISE-Trial-Evaluating-Cobenfy-xanomeline-and-trospium-chloride-as-an-Adjunctive-Treatment-to-Atypical-Antipsychotics-in-Adults-with-Schizophrenia\/default.aspx. Accessed 23 Nov 2025."},{"key":"1259_CR43","unstructured":"Bristol Myers Squibb. In: Alzheimer\u2019s disease clinical trials. https:\/\/www.bmsclinicaltrials.com\/us\/en\/alzheimers-disease. Accessed 23 Nov 2025."},{"key":"1259_CR44","unstructured":"Bristol Myers Squibb. In: Bipolar disorder clinical trials. https:\/\/www.bmsclinicaltrials.com\/us\/en\/bipolar-clinical-trials. Accessed 23 Nov 2025."},{"issue":"5","key":"1259_CR45","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1007\/s00210-024-03757-6","volume":"398","author":"S Dalvi","year":"2025","unstructured":"Dalvi S, Bhatt LK. Trace amine-associated receptor 1 (TAAR1): an emerging therapeutic target for neurodegenerative, neurodevelopmental, and neurotraumatic disorders. Naunyn Schmiedebergs Arch Pharmacol. 2025;398(5):5057\u201375.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"24","key":"1259_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413185","volume":"22","author":"N Dedic","year":"2021","unstructured":"Dedic N, Dworak H, Zeni C, Rutigliano G, Howes OD. Therapeutic potential of TAAR1 agonists in schizophrenia: evidence from preclinical models and clinical studies. Int J Mol Sci. 2021;22(24):13185. https:\/\/doi.org\/10.3390\/ijms222413185.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1259_CR47","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1021\/acsmedchemlett.1c00527","volume":"13","author":"MLR Heffernan","year":"2022","unstructured":"Heffernan MLR, Herman LW, Brown S, Jones PG, Shao L, Hewitt MC, et al. Ulotaront: a TAAR1 agonist for the treatment of schizophrenia. ACS Med Chem Lett. 2022;13(1):92\u20138.","journal-title":"ACS Med Chem Lett"},{"key":"1259_CR48","doi-asserted-by":"publisher","DOI":"10.12688\/wellcomeopenres.21302.1","volume":"9","author":"S Siafis","year":"2024","unstructured":"Siafis S, Chiocchia V, Macleod MR, Austin C, Homiar A, Tinsdeall F, et al. Trace amine-associated receptor 1 (TAAR1) agonism for psychosis: a living systematic review and meta-analysis of human and non-human data. Wellcome Open Res. 2024;9:182. https:\/\/doi.org\/10.12688\/wellcomeopenres.21302.1. (eCollection 2024).","journal-title":"Wellcome Open Res"},{"issue":"10202","key":"1259_CR49","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939\u201351.","journal-title":"Lancet"},{"issue":"3","key":"1259_CR50","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1192\/bjp.2024.237","volume":"226","author":"KA Smith","year":"2025","unstructured":"Smith KA, Boyce N, Chevance A, Chiocchia V, Correll CU, Donoghue K, et al. Triangulating evidence from the GALENOS living systematic review on trace amine-associated receptor 1 (TAAR1) agonists in psychosis. Br J Psychiatry. 2025;226(3):162\u201370.","journal-title":"Br J Psychiatry"},{"issue":"16","key":"1259_CR51","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1056\/NEJMoa1911772","volume":"382","author":"KS Koblan","year":"2020","unstructured":"Koblan KS, Kent J, Hopkins SC, Krystal JH, Cheng H, Goldman R, et al. A non-D2-receptor-binding drug for the treatment of schizophrenia. N Engl J Med. 2020;382(16):1497\u2013506.","journal-title":"N Engl J Med"},{"issue":"1","key":"1259_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-021-00190-z","volume":"7","author":"CU Correll","year":"2021","unstructured":"Correll CU, Koblan KS, Hopkins SC, Li Y, Heather D, Goldman R, et al. Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study. NPJ Schizophr. 2021;7(1):63. https:\/\/doi.org\/10.1038\/s41537-021-00190-z.","journal-title":"NPJ Schizophr"},{"key":"1259_CR53","unstructured":"Sumitomo Pharma Inc. Sumitomo Pharma and Otsuka Announce Topline results from phase 3 DIAMOND 1 and DIAMOND 2 clinical studies evaluating ulotaront in schizophrenia. In: News Room. July 31, 2023. https:\/\/www.sumitomo-pharma.com\/news\/20230731-1.html. Accessed 23 Nov 2025."},{"issue":"9","key":"1259_CR54","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/ijnp\/pyad049","volume":"26","author":"R \u00c5gren","year":"2023","unstructured":"\u00c5gren R, Betari N, Saarinen M, Zeberg H, Svenningsson P, Sahlholm K. In vitro comparison of ulotaront (SEP-363856) and ralmitaront (RO6889450): two TAAR1 agonist candidate antipsychotics. Int J Neuropsychopharmacol. 2023;26(9):599\u2013606.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"7","key":"1259_CR55","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00406-023-01580-3","volume":"273","author":"ED Achtyes","year":"2023","unstructured":"Achtyes ED, Hopkins SC, Dedic N, Dworak H, Zeni C, Koblan K. Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2023;273(7):1543\u201356.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"5","key":"1259_CR56","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1080\/13543784.2023.2206559","volume":"32","author":"GH Le","year":"2023","unstructured":"Le GH, Gillissie ES, Rhee TG, Cao B, Alnefeesi Y, Guo Z, et al. Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials. Expert Opin Investig Drugs. 2023;32(5):401\u201315.","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"1259_CR57","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/s41386-023-01779-x","volume":"49","author":"SM Yang","year":"2024","unstructured":"Yang SM, Ghoshal A, Hubbard JM, Gacki\u00e8re F, Teyssi\u00e9 R, Neale SA, et al. TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner. Neuropsychopharmacol. 2024;49(7):1091\u2013103.","journal-title":"Neuropsychopharmacol"},{"key":"1259_CR58","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.schres.2017.01.043","volume":"189","author":"M Cantillon","year":"2017","unstructured":"Cantillon M, Prakash A, Alexander A, Ings R, Sweitzer D, Bhat L. Dopamine serotonin stabilizer RP5063: a randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder. Schizophr Res. 2017;189:126\u201333.","journal-title":"Schizophr Res"},{"key":"1259_CR59","unstructured":"Reviva Pharmaceuticals. Reviva announces FDA alignment on brilaroxazine clinical trials for NDA in schizophrenia. In: Press Releases. April 15, 2024. https:\/\/revivapharma.com\/reviva-announces-fda-alignment-on-brilaroxazine-clinical-trials-for-nda-in-schizophrenia\/. Accessed 23 Nov 2025."},{"key":"1259_CR60","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejphar.2017.05.048","volume":"810","author":"L Bhat","year":"2017","unstructured":"Bhat L, Hawkinson J, Cantillon M, Reddy DG, Bhat SR, Laurent CE, et al. RP5063, a novel, multimodal, serotonin receptor modulator, prevents monocrotaline-induced pulmonary arterial hypertension in rats. Eur J Pharmacol. 2017;810:92\u20139.","journal-title":"Eur J Pharmacol"},{"key":"1259_CR61","unstructured":"Kuntz L. New positive results for NBI-1117568 in adults with schizophrenia. Psychiatric Times. In. Psychiatric Times. August 28, 2024. https:\/\/www.psychiatrictimes.com\/view\/new-positive-results-for-nbi-1117568-in-adults-with-schizophrenia. Accessed 23 Nov 2025."},{"key":"1259_CR62","unstructured":"Neurocrine Biosciences: Neurocrine Biosciences reports positive phase 2 data for NBI-1117568 in adults with schizophrenia. In: News Releases Details. August 28, 2024. https:\/\/neurocrine.gcs-web.com\/news-releases\/news-release-details\/neurocrine-biosciences-reports-positive-phase-2-data-nbi-1117568. Accessed 23 Nov 2025."},{"key":"1259_CR63","unstructured":"Neurocrine Biosciences: Neurocrine Biosciences initiates phase 3 registrational program for NBI-1117568 as potential treatment for adults with schizophrenia. In: PR Newswire. May 28, 2025. https:\/\/www.prnewswire.com\/news-releases\/neurocrine-biosciences-presents-new-positive-data-from-phase-2-study-of-nbi-1117568-in-adults-with-schizophrenia-at-american-society-of-clinical-psychopharmacology-2025-302467554.html. Accessed 23 Nov 2025."},{"key":"1259_CR64","unstructured":"MapLight Therapeutics: MapLight Therapeutics announces completion of phase 1 clinical trial for ML-007, a novel therapy for the treatment of schizophrenia and dyskinesias. In: MapLight News. August 18, 2022. https:\/\/maplightrx.com\/maplight-therapeutics-announces-completion-of-phase-1-clinical-trial-for-ml-007-a-novel-therapy-for-the-treatment-of-schizophrenia-and-dyskinesias\/. Accessed 23 Nov 2025."},{"key":"1259_CR65","unstructured":"MapLight Therapeutics: MapLight Therapeutics announces successful completion of second phase 1 clinical trial of the novel muscarinic receptor agonist ML-007. In: MapLight News. August 24, 2023. https:\/\/maplightrx.com\/agonist-ml-007\/. Accessed 23 Nov 2025."},{"key":"1259_CR66","unstructured":"MapLight Therapeutics: MapLight Therapeutics announces completion of phase 1 clinical trial for novel M1\/M4 muscarinic agonist in development for schizophrenia and Alzheimer\u2019s disease psychosis. In: MapLight News. January 3, 2024. https:\/\/maplightrx.com\/maplight-therapeutics-announces-completion-of-phase-1-clinical-trial-for-novel-m1-m4-muscarinic-agonist-in-development-for-schizophrenia-and-alzheimers-disease-psychosis\/. Accessed 23 Nov 2025."},{"key":"1259_CR67","unstructured":"MapLight Therapeutics: MapLight Therapeutics Announces initiation of phase 2 trial of its novel M1\/M4 muscarinic agonist ML-007C-MA for the treatment of schizophrenia. In: MapLight News. July 8, 2025. https:\/\/www.prnewswire.com\/news-releases\/maplight-therapeutics-announces-initiation-of-phase-2-trial-of-its-novel-m1m4-muscarinic-agonist-ml-007c-ma-for-the-treatment-of-schizophrenia-302497995.html. Accessed 23 Nov 2025."},{"key":"1259_CR68","unstructured":"MapLight Therapeutics. MapLight Therapeutics pipeline. In: Our product pipeline. https:\/\/maplightrx.com\/pipeline\/. Accessed 23 Nov 2025."},{"key":"1259_CR69","unstructured":"Deswal P. MapLight mulls muscarinic therapy for Alzheimer\u2019s disease. In: Clinical trials arena. August 25, 2023. https:\/\/www.clinicaltrialsarena.com\/news\/maplight-mulls-muscarinic-therapy-for-alzheimers-disease\/. Accessed 23 Nov 2025."},{"key":"1259_CR70","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.83477","volume":"12","author":"Z Vuckovic","year":"2023","unstructured":"Vuckovic Z, Wang J, Pham V, Mobbs JI, Belousoff MJ, Bhattarai A, et al. Pharmacological hallmarks of allostery at the M4 muscarinic receptor elucidated through structure and dynamics. eLife. 2023;12:e83477. https:\/\/doi.org\/10.7554\/eLife.83477.","journal-title":"eLife"},{"key":"1259_CR71","unstructured":"NeuShen Therapeutics: NeuShen Therapeutics initiates first-in-human trial of NS-136, a novel selective M4 receptor positive allosteric modulator for the treatment of schizophrenia. In: PR Newswire. May 8, 2024. https:\/\/www.prnewswire.com\/news-releases\/neushen-therapeutics-initiates-first-in-human-trial-of-ns-136-a-novel-selective-m4-receptor-positive-allosteric-modulator-for-the-treatment-of-schizophrenia-302139628.html. Accessed 23 Nov 2025."},{"issue":"9","key":"1259_CR72","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1007\/s00213-022-06185-7","volume":"239","author":"L Biernat","year":"2022","unstructured":"Biernat L, Grattan VT, Hixon MS, Prensky Z, Vaino AR. A randomized, double-blind, placebo controlled, phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of LB-102, a selective dopamine D(2\/3)\/5-HT(7) inhibitor. Psychopharmacology. 2022;239(9):3009\u201318.","journal-title":"Psychopharmacology"},{"key":"1259_CR73","unstructured":"LB Pharmaceuticals Inc. LB Pharmaceuticals announces positive topline results from phase 2 trial of LB-102 in schizophrenia. In: GlobeNewswire. January 8, 2025. https:\/\/www.globenewswire.com\/news-release\/2025\/01\/08\/3006104\/0\/en\/LB-Pharmaceuticals-Announces-Positive-Topline-Results-from-Phase-2-Trial-of-LB-102-in-Schizophrenia.html. Accessed 23 Nov 2025."},{"key":"1259_CR74","unstructured":"Tattory M. LB Pharmaceuticals to present three posters at 38th ECNP Congress highlighting clinical activity and safety profile of LB-102 in schizophrenia, including positive effects on cognition and negative symptoms. In: Press Releases. October 6, 2025. https:\/\/ir.lbpharma.us\/press_releases\/lb-pharmaceuticals-to-present-three-posters-at-38th-ecnp-congress-highlighting-clinical-activity-and-safety-profile-of-lb-102-in-schizophrenia-including-positive-effects-on-cognition-and-negative-sym\/. Accessed 23 Nov 2025."},{"key":"1259_CR75","doi-asserted-by":"crossref","unstructured":"Eramo A, Callahan L, Bassani NL, B. P., Prensky Z, Vaino AR, Kane JM. LB-102 for cognitive impairment in schizophrenia: exploratory post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study. In: Poster presentation at the 38th European College of Neuropsychopharmacology (ECNP) conference in Amsterdam (October 11\u201314, 2025). Poster PS03-2276 (presented October 13, 2025).","DOI":"10.1016\/j.nsa.2025.106402"},{"issue":"s1","key":"1259_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.nsa.2025.106835","volume":"5","author":"A Eramo","year":"2026","unstructured":"Eramo A, Callahan L, Bassani N, Lee BP, Vaino AR, Kane JM. LB-102 for acute schizophrenia in adults: results from the phase 2 clinical trial (NOVA1) with a focus on negative symptoms. Neurosci Appl. 2026;5(s1):106835. https:\/\/doi.org\/10.1016\/j.nsa.2025.106835.","journal-title":"Neurosci Appl"},{"issue":"s1","key":"1259_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.nsa.2025.106836","volume":"5","author":"A Eramo","year":"2026","unstructured":"Eramo A, Callahan L, Bassani N, Lee BP, Prensky Z, Vaino AR, Kane JM. LB-102 for acute schizophrenia in adults: efficacy and safety from a large phase 2 clinical trial. Neurosci Appl 2026;5(s1):106836. https:\/\/doi.org\/10.1016\/j.nsa.2025.106836.","journal-title":"Neurosci Appl"},{"issue":"2","key":"1259_CR78","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyae005","volume":"27","author":"R Singh","year":"2024","unstructured":"Singh R, Hahn MK, Bansal Y, Agarwal SM, Remington G. Evenamide: a potential pharmacotherapeutic alternative for treatment-resistant schizophrenia. Int J Neuropsychopharmacol. 2024;27(2):pyae005. https:\/\/doi.org\/10.1093\/ijnp\/pyae005.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"8","key":"1259_CR79","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/ijnp\/pyad035","volume":"26","author":"R Anand","year":"2023","unstructured":"Anand R, Turolla A, Chinellato G, Roy A, Hartman RD. Phase 2 results indicate evenamide, a selective modulator of glutamate release, is associated with clinically important long-term efficacy when added to an antipsychotic in patients with treatment-resistant schizophrenia. Int J Neuropsychopharmacol. 2023;26(8):523\u20138.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1259_CR80","unstructured":"Newron Pharmaceuticals. Newron announces approval for pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS). In: News and Events. May 12, 2025. https:\/\/www.newron.com\/news-and-media\/regulatory-news\/newron-announces-approval-pivotal-phase-iii-enigma-trs-program. Accessed 23 Nov 2025."},{"issue":"5","key":"1259_CR81","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1080\/03007995.2020.1729708","volume":"36","author":"S Tonstad","year":"2020","unstructured":"Tonstad S, Arons C, Rollema H, Berlin I, Hajek P, Fagerstr\u00f6m K, et al. Varenicline: mode of action, efficacy, safety and accumulated experience salient for clinical populations. Curr Med Res Opin. 2020;36(5):713\u201330.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"1259_CR82","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/npp.2011.238","volume":"37","author":"JC Shim","year":"2012","unstructured":"Shim JC, Jung DU, Jung SS, Seo YS, Cho DM, Lee JH, et al. Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial. Neuropsychopharmacology. 2012;37(3):660\u20138.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"1259_CR83","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00213-019-05396-9","volume":"237","author":"T Tanzer","year":"2020","unstructured":"Tanzer T, Shah S, Benson C, De Monte V, Gore-Jones V, Rossell SL, et al. Varenicline for cognitive impairment in people with schizophrenia: systematic review and meta-analysis. Psychopharmacology. 2020;237(1):11\u20139.","journal-title":"Psychopharmacology"},{"issue":"9","key":"1259_CR84","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/S2215-0366(20)30261-3","volume":"7","author":"DJ Siskind","year":"2020","unstructured":"Siskind DJ, Wu BT, Wong TT, Firth J, Kisely S. Pharmacological interventions for smoking cessation among people with schizophrenia spectrum disorders: a systematic review, meta-analysis, and network meta-analysis. Lancet Psychiatry. 2020;7(9):762\u201374.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"1259_CR85","doi-asserted-by":"publisher","first-page":"18508","DOI":"10.1038\/s41598-025-93256-2","volume":"15","author":"C Wu","year":"2025","unstructured":"Wu C, Dagg P, Molgat C, Grishin N. Smoking prevalence and correlates among inpatients with schizophrenia or schizoaffective disorder. Sci Rep. 2025;15(1):18508. https:\/\/doi.org\/10.1038\/s41598-025-93256-2.","journal-title":"Sci Rep"},{"key":"1259_CR86","unstructured":"Boehringer-Ingelheim. CT-155 (BI 3972080): Prescription digital therapeutic. In: Mental health pipeline. https:\/\/www.boehringer-ingelheim.com\/science-innovation\/human-health-innovation\/clinical-pipeline\/ct-155-bi-3972080-prescription-digital-therapeutic. Accessed 23 Nov 2025."},{"key":"1259_CR87","unstructured":"Boehringer-Ingelheim. Boehringer and Click Therapeutics present pivotal data for investigational prescription digital therapeutic CT-155 showing a statistically significant reduction in negative symptoms of schizophrenia. In: PR Newswire. October 13, 2025. https:\/\/www.prnewswire.com\/news-releases\/boehringer-and-click-therapeutics-present-pivotal-data-for-investigational-prescription-digital-therapeutic-ct-155-showing-a-statistically-significant-reduction-in-negative-symptoms-of-schizophrenia-302582119.html. Accessed 23 Nov 2025."},{"key":"1259_CR88","unstructured":"Boehringer-Ingelheim: Boehringer Ingelheim and Click Therapeutics receive FDA breakthrough device designation for schizophrenia prescription digital therapeutic. In: Mental Health. April 1, 2024. https:\/\/www.boehringer-ingelheim.com\/human-health\/mental-health\/schizophrenia\/fda-grants-breakthrough-status-schizophrenia-treatment. Accessed 23 Nov 2025."},{"key":"1259_CR89","unstructured":"Cerevel Therapeutics: Cerevel Therapeutics announces positive topline results for CVL-231 in phase 1b clinical trial in patients with schizophrenia. In: News Center. June 29, 2021. https:\/\/news.abbvie.com\/2021-06-29-Cerevel-Therapeutics-Announces-Positive-Topline-Results-for-CVL-231-in-Phase-1b-Clinical-Trial-in-Patients-with-Schizophrenia. Accessed 23 Nov 2025."},{"key":"1259_CR90","unstructured":"AbbVie. AbbVie provides update on phase 2 results for emraclidine in schizophrenia. In: News Center. November 11, 2024. https:\/\/news.abbvie.com\/2024-11-11-AbbVie-Provides-Update-on-Phase-2-Results-for-Emraclidine-in-Schizophrenia. Accessed 23 Nov 2025."},{"key":"1259_CR91","unstructured":"AbbVie. AbbVie provides update on phase 2 results for emraclidine in schizophrenia. In: PR Newswire. November 11, 2024. https:\/\/www.prnewswire.com\/news-releases\/abbvie-provides-update-on-phase-2-results-for-emraclidine-in-schizophrenia-302301190.html. Accessed 23 Nov 2025."},{"issue":"12","key":"1259_CR92","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1176\/appi.ajp.2017.17010122","volume":"174","author":"M Davidson","year":"2017","unstructured":"Davidson M, Saoud J, Staner C, Noel N, Luthringer E, Werner S, et al. Efficacy and safety of MIN-101: a 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia. Am J Psychiatry. 2017;174(12):1195\u2013202.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"1259_CR93","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/schbul\/sbac013","volume":"48","author":"M Davidson","year":"2022","unstructured":"Davidson M, Saoud J, Staner C, Noel N, Werner S, Luthringer E, et al. Efficacy and safety of roluperidone for the treatment of negative symptoms of schizophrenia. Schizophr Bull. 2022;48(3):609\u201319.","journal-title":"Schizophr Bull"},{"key":"1259_CR94","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.schres.2023.03.028","volume":"255","author":"J Rabinowitz","year":"2023","unstructured":"Rabinowitz J, Staner C, Saoud J, Weiser M, Kuchibhatla R, Davidson M, et al. Long-term effects of roluperidone on negative symptoms of schizophrenia. Schizophr Res. 2023;255:9\u201313.","journal-title":"Schizophr Res"},{"key":"1259_CR95","unstructured":"Minerva Neurosciences. Minerva Neurosciences announces the results of the phase 3 trial of roluperidone for the treatment of negative symptoms of schizophrenia following the completion of the 40-week open-label extension. In: News Releases. May 11, 2021. https:\/\/ir.minervaneurosciences.com\/news-releases\/news-release-details\/minerva-neurosciences-announces-results-phase-3-trial-0. Accessed 23 Nov 2025."},{"key":"1259_CR96","unstructured":"Minerva Neurosciences. Minerva Neurosciences receives complete response letter from FDA for new drug application for roluperidone for the treatment of negative symptoms in patients with schizophrenia. Press Release. February 27, 2024. https:\/\/ir.minervaneurosciences.com\/node\/11406\/pdf. Accessed 23 Nov 2025."},{"key":"1259_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115028","volume":"200","author":"AB Casey","year":"2022","unstructured":"Casey AB, Cui M, Booth RG, Canal CE. \u201cSelective\u201d serotonin 5-HT(2A) receptor antagonists. Biochem Pharmacol. 2022;200:115028. https:\/\/doi.org\/10.1016\/j.bcp.2022.115028. (Epub 2022 Apr 4).","journal-title":"Biochem Pharmacol"},{"key":"1259_CR98","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.neubiorev.2021.11.032","volume":"132","author":"MC Lobo","year":"2022","unstructured":"Lobo MC, Whitehurst TS, Kaar SJ, Howes OD. New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics. Neurosci Biobehav Rev. 2022;132:324\u201361.","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"1259_CR99","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S2215-0366(21)00386-2","volume":"9","author":"D Bugarski-Kirola","year":"2022","unstructured":"Bugarski-Kirola D, Arango C, Fava M, Nasrallah H, Liu IY, Abbs B, et al. Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe. Lancet Psychiatry. 2022;9(1):46\u201358.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"1259_CR100","doi-asserted-by":"publisher","DOI":"10.1093\/schizbullopen\/sgac006","volume":"3","author":"D Bugarski-Kirola","year":"2022","unstructured":"Bugarski-Kirola D, Bitter I, Liu IY, Abbs B, Stankovic S. ENHANCE: phase 3, randomized, double-blind, placebo-controlled study of adjunctive pimavanserin for schizophrenia in patients with an inadequate response to antipsychotic treatment. Schizophr Bull Open. 2022;3(1):sgac006. https:\/\/doi.org\/10.1093\/schizbullopen\/sgac006. (eCollection 2022 Jan).","journal-title":"Schizophr Bull Open"},{"key":"1259_CR101","doi-asserted-by":"publisher","unstructured":"Bugarski-Kirola D, Liu IY, Arango C, Marder SR. A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pimavanserin as an adjunctive treatment for the negative symptoms of schizophrenia (ADVANCE-2) in patients with predominant negative symptoms. Schizophr Bull. 2025;sbaf034. https:\/\/doi.org\/10.1093\/schbul\/sbaf034. (Online ahead of print).","DOI":"10.1093\/schbul\/sbaf034"},{"key":"1259_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173635","volume":"890","author":"C Cosi","year":"2021","unstructured":"Cosi C, Martel JC, Auclair AL, Collo G, Cavalleri L, Heusler P, et al. Pharmacology profile of F17464, a dopamine D(3) receptor preferential antagonist. Eur J Pharmacol. 2021;890:173635. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173635. (Epub 2020 Oct 14).","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"1259_CR103","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1124\/jpet.109.160432","volume":"333","author":"B Kiss","year":"2010","unstructured":"Kiss B, Horv\u00e1th A, N\u00e9methy Z, Schmidt E, Laszlovszky I, Bugovics G, et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)\/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333(1):328\u201340.","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"1259_CR104","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1038\/s41386-019-0355-2","volume":"44","author":"I Bitter","year":"2019","unstructured":"Bitter I, Lieberman JA, Gaudoux F, Sokoloff P, Groc M, Chavda R, et al. Randomized, double-blind, placebo-controlled study of F17464, a preferential D(3) antagonist, in the treatment of acute exacerbation of schizophrenia. Neuropsychopharmacology. 2019;44(11):1917\u201324.","journal-title":"Neuropsychopharmacology"},{"key":"1259_CR105","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.schres.2024.05.019","volume":"270","author":"Y Mukai","year":"2024","unstructured":"Mukai Y, Lupinacci R, Marder S, Snow-Adami L, Voss T, Smith SM, et al. Effects of PDE10A inhibitor MK-8189 in people with an acute episode of schizophrenia: a randomized proof-of-concept clinical trial. Schizophr Res. 2024;270:37\u201343.","journal-title":"Schizophr Res"},{"issue":"2","key":"1259_CR106","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19r12960","volume":"81","author":"M Gopalakrishnan","year":"2020","unstructured":"Gopalakrishnan M, Zhu H, Farchione TR, Mathis M, Mehta M, Uppoor R, et al. The trend of increasing placebo response and decreasing treatment effect in schizophrenia trials continues: an update from the US Food and Drug Administration. J Clin Psychiatry. 2020;81(2):19r12960. https:\/\/doi.org\/10.4088\/JCP.19r12960.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"1259_CR107","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/schbul\/sbac061","volume":"48","author":"P Czobor","year":"2022","unstructured":"Czobor P, Kakuszi B, Bitter I. Placebo response in trials of negative symptoms in schizophrenia: a critical reassessment of the evidence. Schizophr Bull. 2022;48(6):1228\u201340.","journal-title":"Schizophr Bull"},{"key":"1259_CR108","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20250034","author":"JT Kantrowitz","year":"2025","unstructured":"Kantrowitz JT, Mayer MR, Choo T-H, Liu K, Govani V, Francis S, et al. Effect size deflation with increasing sample size in adjunctive trials for negative symptoms in schizophrenia: a meta-analysis and meta-regression across mechanisms of action. Am J Psychiatry. 2025. https:\/\/doi.org\/10.1176\/appi.ajp.20250034.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"1259_CR109","first-page":"29","volume":"39","author":"J Yoon","year":"2025","unstructured":"Yoon J, Mayer MR, Berro T, Brazis S, Kantrowitz JT. Knowing is half the battle: the factors leading to efficient recruitment of representative samples in schizophrenia research. Pharmaceut Med. 2025;39(1):29\u201338.","journal-title":"Pharmaceut Med"},{"issue":"8","key":"1259_CR110","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/jamapsychiatry.2017.1574","volume":"74","author":"RSE Keefe","year":"2017","unstructured":"Keefe RSE, Davis VG, Harvey PD, Atkins AS, Haig GM, Hagino O, et al. Placebo response and practice effects in schizophrenia cognition trials. JAMA Psychiat. 2017;74(8):807\u201314.","journal-title":"JAMA Psychiat"},{"issue":"8","key":"1259_CR111","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.biopsych.2024.01.009","volume":"96","author":"KH Preller","year":"2024","unstructured":"Preller KH, Scholpp J, Wunder A, Rosenbrock H. Neuroimaging biomarkers for drug discovery and development in schizophrenia. Biol Psychiatry. 2024;96(8):666\u201373.","journal-title":"Biol Psychiatry"},{"issue":"3","key":"1259_CR112","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/tpj.2010.90","volume":"12","author":"W Liu","year":"2012","unstructured":"Liu W, Downing AC, Munsie LM, Chen P, Reed MR, Ruble CL, et al. Pharmacogenetic analysis of the mGlu2\/3 agonist LY2140023 monohydrate in the treatment of schizophrenia. Pharmacogenomics J. 2012;12(3):246\u201354.","journal-title":"Pharmacogenomics J"},{"issue":"20","key":"1259_CR113","doi-asserted-by":"publisher","first-page":"8485","DOI":"10.1073\/pnas.1103029108","volume":"108","author":"FG Revel","year":"2011","unstructured":"Revel FG, Moreau JL, Gainetdinov RR, Bradaia A, Sotnikova TD, Mory R, et al. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc Natl Acad Sci USA. 2011;108(20):8485\u201390.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1259_CR114","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.neuroscience.2024.07.037","volume":"578","author":"S Supplisson","year":"2025","unstructured":"Supplisson S. Dynamic role of GlyT1 as glycine sink or source: pharmacological implications for the gain control of NMDA receptors. Neuroscience. 2025;578:59\u201368.","journal-title":"Neuroscience"},{"issue":"2","key":"1259_CR115","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/wps.21078","volume":"22","author":"A Abi-Dargham","year":"2023","unstructured":"Abi-Dargham A, Moeller SJ, Ali F, DeLorenzo C, Domschke K, Horga G, et al. Candidate biomarkers in psychiatric disorders: state of the field. World Psychiatry. 2023;22(2):236\u201362.","journal-title":"World Psychiatry"},{"issue":"2","key":"1259_CR116","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1176\/appi.ajp.2007.07010042","volume":"165","author":"KH Nuechterlein","year":"2008","unstructured":"Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165(2):203\u201313.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1259_CR117","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/schbul\/sbae051","volume":"51","author":"KH Nuechterlein","year":"2025","unstructured":"Nuechterlein KH, Nasrallah H, Velligan D. Measuring cognitive impairments associated with schizophrenia in clinical practice: overview of current challenges and future opportunities. Schizophr Bull. 2025;51(2):401\u201321.","journal-title":"Schizophr Bull"},{"key":"1259_CR118","unstructured":"Formulary Watch: FDA approves the oral medication KarXT for schizophrenia. In: Managed Health Care Executive. September 27, 2024. https:\/\/www.managedhealthcareexecutive.com\/view\/fda-approves-the-oral-medication-karxt-for-schizophrenia. Accessed 23 Nov 2025."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01259-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01259-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01259-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:07:08Z","timestamp":1771430828000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01259-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":118,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1259"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01259-4","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.Z. has received research support from Reshape (Rovi, clinical trial) and travel grants and speaker fees from Otsuka Lundbeck, Rovi, and Boehringer Ingelheim. S.E. declares no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"S.E. and M.Z. contributed equally to this manuscript, including conceptualization, literature review, analysis, drafting, and critical revision. Both authors have read and approved the final version of the manuscript and agree to be accountable for all aspects of the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}